Search News

New Group of Oral Hepatitis C Drugs Near U.S. Approval – 10/24/2013

October 24, 2013 — Patients infected with the liver-destroying hepatitis C virus should soon have better treatment options as new tablets from Gilead Sciences and others approach U.S. regulatory approval.

Gilead's experimental drug sofosbuvir is the first of a new group of oral therapies to be considered by the U.S. Food and Drug Administration, which has convened an advisory panel for Friday.